Market Pulse59Neutral

Gilead Sciences, Inc.Opportunity Rank #158(GILD) Intrinsic Value & DCF Analysis (2026)

Sector: Healthcare

Current Price

$134.06

Last updated: May 08, 2026

Price vs Intrinsic Value

$134.06
Price
$171.88
Intrinsic Value
Undervalued by 28%MOS: $137.50

Fundamental Score

64/100
Neutral

Weighted across 6 signals

Narrative Score

68/100
Improving

-6 vs previous

Trend Score

34/100
Weak

As of 2026-05-08

The intrinsic value of Gilead Sciences, Inc. (GILD) is estimated at $171.88 per share based on a 10-year discounted cash flow (DCF) analysis. At the current price of $134.06, the stock appears undervalued relative to its projected cash flow fundamentals. This estimate assumes a 4.17% long-term growth rate and an 8.50% discount rate (calculated: 8.28%), reflecting expected future free cash flow and cost of capital.

The intrinsic value of Gilead Sciences, Inc. (GILD) is estimated at $171.88 per share based on a 10-year discounted cash flow (DCF) analysis. At the current price of $134.06, the stock appears undervalued relative to its projected cash flow fundamentals. This estimate assumes a 4.17% long-term growth rate and an 8.50% discount rate (calculated: 8.28%), reflecting expected future free cash flow and cost of capital.

Valuation Details

$171.88
▲ 28.21% upside
20% margin of safety: $137.50
Years: 10Growth Rate: 4.17%
Want to create your own valuation? Create a free account.

Capital Efficiency

Average Quarterly ROIC
5.13%
Cost of Capital (estimated)10%
Value StatusUnderperforming Capital

The company is earning below its required return. This may indicate inefficient use of capital or excess cash that isn't being reinvested.

Complete historical ROIC is available with
.

Fundamental Details

64/100
NeutralWeighted across 6 signals
DCF Discount
28.2% discount to price
97
FCF Yield
6.8% trailing FCF yield
100
ROIC vs WACC
ROIC 5.1% vs WACC 10.0% (0.5x)
26
Net Debt / FCF
Net cash position
100
Buybacks
Share count growing
30
FCF CAGR (5Y)
5.2% 5Y FCF CAGR
51
Strengths: DCF Discount, FCF Yield. Concerns: ROIC vs WACC, Buybacks.

Narrative Details

68/100
Improving
-6 vs previous · +2 new driversVs 6-Month Baseline:Below Avg (20th pct)Weighted across 5 recent drivers
Trend: Deteriorating downConfidence: 100%Updated: 18h ago
Sources: 119 (108 News · 11 Analyst)
Drivers(last 30 days)
78 news sentiment+1.1
27 regulatory scrutiny+0.5
2 earnings beat+0.1
Legal risk+0.1
11 analyst reiterations0.0

Trend Details

34/100
WeakAs of 2026-05-08311 daily bars used
3M Relative Strength vs SPY-20.7%
Distance from 52-Week High-15.7%
Price vs 50 EMA-3.8%
Price vs 21 EMA37 · -2.1%
Price vs 50 EMA32 · -3.8%
21 EMA vs 50 EMA36 · -1.8%
3M RS vs SPY3 · -20.7%
6M RS vs SPY45 · -1.7%
Distance from 52W High69 · -15.7%

Investment Coach

Updating... 1d ago
BUYConfidence: 64%
Thesis
Gilead Sciences, Inc. is undervalued with an estimated fair value 32.4% above the current price, supported by constructive fundamentals and a strong narrative score. Despite trailing returns relative to its cost of capital, the company shows potential for upside based on its free cash flow yield and valuation metrics.
Key Risk
The key risk is the deteriorating narrative trend combined with a negative spread between ROIC and WACC, which may pressure future returns and valuation.
Signals To Watch
  • Monitor whether valuation discount remains above 10%.
  • Track ROIC vs WACC spread for sustained improvement.
  • Follow narrative trend for meaningful shifts in the score direction.
Ask the Coach - Available with
Historical Growth Rates
Free Cash Flow- - -Trend CAGR: 4.17%5 Year CAGR (Adjusted): -0.50%

Free Cash Flow (in millions)

TTM20252024202320222021202020192018201720162015201420132012201120102009200820072006
$11,381$10,582$11,351$8,591$9,800$11,963$8,818$9,969$9,324$12,488$17,795$21,997$13,375$3,295$3,592$3,771$2,896$3,310$2,258$1,844$1,323

How Intrinziq Estimates Fair Value

Intrinziq estimates Gilead Sciences, Inc.'s intrinsic value using a discounted cash flow (DCF) model based on free cash flow trends and a market-based discount rate. The model projects future cash flows over ten years and discounts them using a market return assumption to estimate fair value.

Gilead Sciences, Inc.Healthcare

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.